NASDAQ:ENSC Ensysce Biosciences (ENSC) Stock Price, News & Analysis $0.52 0.00 (0.00%) Closing price 08/7/2026 04:00 PM EasternExtended Trading$0.48 -0.04 (-7.54%) As of 05:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Ensysce Biosciences Stock (NASDAQ:ENSC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ensysce Biosciences alerts:Sign Up Key Stats Today's Range$0.47▼$0.5550-Day Range$0.25▼$0.5252-Week Range$0.23▼$2.75Volume15.37 million shsAverage Volume42.47 million shsMarket Capitalization$8.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features. The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations. Ensysce is advancing ENS100 through preclinical studies and regulatory interactions, with the goal of submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). Beyond pain management, the platform underpins additional pipeline programs targeting other central nervous system indications where controlled drug delivery may enhance therapeutic benefit and safety. Founded with a mission to address critical public health challenges, Ensysce Biosciences operates primarily in the United States and engages in collaborative partnerships to support its research and development activities. The company holds a portfolio of issued patents and pending applications covering its enzyme-activated prodrug technologies, reflecting a commitment to innovation in the design of safer pharmaceutical therapies.AI Generated. May Contain Errors. Read More Ensysce Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreENSC MarketRank™: Ensysce Biosciences scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingEnsysce Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageEnsysce Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Ensysce Biosciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ensysce Biosciences are expected to grow in the coming year, from ($1.53) to ($0.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ensysce Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ensysce Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnsysce Biosciences has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Ensysce Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.70% of the float of Ensysce Biosciences has been sold short.Short Interest Ratio / Days to CoverEnsysce Biosciences has a short interest ratio ("days to cover") of 0.18, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ensysce Biosciences has recently increased by 121.18%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnsysce Biosciences does not currently pay a dividend.Dividend GrowthEnsysce Biosciences does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.49 News SentimentEnsysce Biosciences has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Ensysce Biosciences this week, compared to 2 articles on an average week.Search Interest5 people have searched for ENSC on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows1 people have added Ensysce Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ensysce Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders2.80% of the stock of Ensysce Biosciences is held by insiders.Percentage Held by Institutions5.63% of the stock of Ensysce Biosciences is held by institutions.Read more about Ensysce Biosciences' insider trading history. Receive ENSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENSC Stock News HeadlinesEnsysce Biosciences (ENSC) Projected to Release Earnings on Wednesday1 hour ago | americanbankingnews.comEnsysce Biosciences (NASDAQ:ENSC) Stock Rating Upgraded by Wall Street ZenAugust 8 at 1:43 AM | americanbankingnews.comBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-largest miner running on fumes. Newmont's $15 billion purchase of Newcrest, the largest mining deal in history, still couldn't keep output growing, proof that majors must keep buying to survive. With record cash flows and shrinking mines, gold majors are positioned to launch a wave of acquisitions targeting the best junior assets. | Golden Portfolio (Ad)Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing - The Globe and MailAugust 7 at 7:09 AM | theglobeandmail.comENSC Makes Bold Move that Bolsters Pipeline and FinancesAugust 6, 2026 | msn.comEnsysce Biosciences completes Cy Biopharma acquisition and secures up to $77 million private financingAugust 6, 2026 | msn.comEnsysce Biosciences Surges After Cy Biopharma Acquisition and Large Financing PackageAugust 6, 2026 | quiverquant.comQEnsysce Biosciences Inc Ordinary Shares ENSCAugust 5, 2026 | morningstar.comMSee More Headlines ENSC Stock Analysis - Frequently Asked Questions How have ENSC shares performed this year? Ensysce Biosciences' stock was trading at $0.92 at the start of the year. Since then, ENSC stock has decreased by 43.5% and is now trading at $0.5202. How were Ensysce Biosciences' earnings last quarter? Ensysce Biosciences, Inc. (NASDAQ:ENSC) issued its quarterly earnings results on Friday, May, 15th. The company reported ($0.52) EPS for the quarter, beating analysts' consensus estimates of ($0.73) by $0.21. The company earned $0.96 million during the quarter, compared to analysts' expectations of $1 million. Ensysce Biosciences had a negative trailing twelve-month return on equity of 766.45% and a negative net margin of 250.39%. When did Ensysce Biosciences' stock split? Ensysce Biosciences's stock reverse split on the morning of Friday, March 31st 2023.The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Ensysce Biosciences? Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ensysce Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ensysce Biosciences investors own include Predictive Oncology (POAI), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Meta Platforms (META), Insulet (PODD) and Broadcom (AVGO). Company Calendar Last Earnings5/15/2026Today8/10/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4d) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 As of 4 days ago, ENSC's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ENSC CIK1716947 Webensysce.com Phone858-263-4196FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.18 million Net Margins-250.39% Pretax Margin-250.39% Return on Equity-766.45% Return on Assets-256.59% Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick Ratio0.71 Sales & Book Value Annual Sales$5.07 million Price / Sales1.58 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book0.83Miscellaneous Outstanding Shares15,370,000Free Float14,936,000Market Cap$8.00 million OptionableNot Optionable Beta0.84 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:ENSC) was last updated on 8/10/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump's Next Move Could Shrink Your DollarThere's a plan in Washington being called the 'Mar-a-Lago Accord' - a deliberate strategy to weaken the U.S. d...Priority Gold | SponsoredI’ll Keep This Short… (Huge AI Opportunity)Analyst Ross Givens says the top AI opportunity right now isn't Microsoft, Google, Amazon, Apple, or Nvidia - ...Traders Agency | SponsoredChina is not hedging. It's escaping.China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...Behind the Markets | SponsoredThis Junior Silver Explorer Is Closing In on Its Biggest CatalystA past-producing Nevada silver project holds a historical 36 million ounce silver-equivalent resource, plus mo...Wall Street Logic | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ensysce Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
